Clinical research

IN RECRUITMENT

Protocol GR40349, PHASE III study, multicenter, multinational, randomized, double masked, controlled, with active comparator to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (yosemite). Roche Laboratory.

Stage: In recruitment.

 

Protocol KHB-1801, double-blind, randomized, multicenter dose determination study to evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD). Chengdu Kanghong Biotechnology Co., Ltd.

FINISHED

GX 29185
Multicenter, multicenter, randomized, controlled by simulation, double blind, PHASE III, to evaluate the efficacy and safety of lampalizumab administered intravitreally in patients with geographic atrophy secondary to macular degeneration associated with age.

Laboratory: Roche
Role in the study: Main investigator
Date: 2016 to 2018

 

SAKURA 32-007
Phase III, multinational, multicenter, randomized, double-blind study to evaluate the safety and efficacy of intravitreal injections of DE-109 (three doses) for the treatment of active, non-infectious uveitis of the posterior segment of the eye.

Laboratory: Santen
Role in the study: Main investigator
Date: 2012 to 2014

 

GX 30191
Multicenter, multicenter, randomized, controlled by simulation, double blind, Phase III study, to evaluate the efficacy and safety of Lampalizumab administered intravitreously in patients with geographic atrophy secondary to macular degeneration associated with age.

Laboratory: Roche
Role in the study: Main investigator
Date: Ending 2018